The Effect of APOE ε4 on Alzheimer's Disease Fluid Biomarkers: A Cross‐Sectional Study Based on the COAST
2025

The Effect of APOE ε4 on Alzheimer's Disease Fluid Biomarkers

Sample size: 818 publication 10 minutes Evidence: moderate

Author Information

Author(s): Bote Zhao, Peixi Zang, Meina Quan, Qianqian Wang, Dongmei Guo, Jianping Jia, Wei Wang

Primary Institution: Xuanwu Hospital, Capital Medical University, Beijing, China

Hypothesis

This study aims to analyze the effect of APOE ε4 on fluid biomarkers and the correlations between blood molecules and CSF biomarkers in Alzheimer's Disease patients.

Conclusion

APOE ε4 is associated with accelerated progression of Alzheimer's Disease pathology.

Supporting Evidence

  • APOE ε4 carriers had increased levels of CSF t-tau and p-tau 181.
  • Blood-derived biomolecules correlated with CSF biomarkers in APOE ε4 carriers.
  • APOE ε4 is linked to neuroinflammation and lipid metabolism in Alzheimer's Disease.

Takeaway

This study found that a specific gene variant, APOE ε4, is linked to faster worsening of Alzheimer's Disease and affects certain biomarkers in the blood and brain fluid.

Methodology

The study enrolled 575 AD patients, 131 patients with non-AD dementia, and 112 cognitively normal participants, comparing cerebrospinal fluid and blood biomarkers.

Potential Biases

Self-reported data may introduce recall bias.

Limitations

The study was conducted at a single center with a limited sample size, which may introduce selection biases.

Participant Demographics

Participants included 575 AD patients, 131 non-AD dementia patients, and 112 cognitively normal individuals, aged 50 to 87 years, with 55.9% being female.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1111/cns.70202

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication